Arcadia Biosciences (RKDA) Capital Expenditures (2014 - 2024)

Arcadia Biosciences has reported Capital Expenditures for 11 years, with the latest figure at $3000.0 in Q2 2024.

• For the quarter ending Q2 2024, Capital Expenditures fell 40.0% year-over-year to $3000.0; the trailing twelve-month figure through Mar 2025 stood at $3000.0 (down 83.33% YoY), and the FY2024 full-year result was $16000.0, up 220.0% from the prior year.
• Capital Expenditures for Q2 2024 stood at $3000.0, down from $13000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $971000.0 in Q2 2020, with the low at -$2.0 million in Q4 2020.
• Historically, Capital Expenditures has averaged $83642.9 across 5 years, with a median of $64000.0 in 2021.
• The largest YoY upside for Capital Expenditures was 784.09% in 2020 against a maximum downside of 124.29% in 2020.
• Arcadia Biosciences' Capital Expenditures stood at -$2.0 million in 2020, then surged by 104.47% to $88000.0 in 2021, then sank by 70.45% to $26000.0 in 2022, then plunged by 80.77% to $5000.0 in 2023, then sank by 40.0% to $3000.0 in 2024.
• The last three Capital Expenditures figures came in at $3000.0 (Q2 2024), $13000.0 (Q1 2024), and $5000.0 (Q2 2023), per Business Quant data.